Patents by Inventor Harry C. Dietz

Harry C. Dietz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating vascular Ehlers Danlos syndrome and associated disorders
    Patent number: 11938135
    Abstract: The present invention relates to compositions and methods for treating vascular Ehlers Danlos Syndrome and associated connective tissue disorders.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 26, 2024
    Assignee: The Johns Hopkins University
    Inventors: Harry C. Dietz, Caitlin J. Bowen, Juan Francisco Calderon Giadrosic
  • MAP KINASE PATHWAY TARGETS FOR THE TREATMENT OF MARFAN SYNDROME
    Publication number: 20240025982
    Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.
    Type: Application
    Filed: May 25, 2023
    Publication date: January 25, 2024
    Inventors: Harry C. Dietz, Jefferson J. Doyle, Alexander J. Doyle
  • TREATMENT OF VASCULAR EHLERS-DANLOS SYNDROME AND RELATED SYNDROMES
    Publication number: 20230310537
    Abstract: Provided herein are, inter alia, method and compositions for treating vascular Ehlers-Danlos syndrome and related syndromes. Also included herein are kits for treating vascular Ehlers-Danlos syndrome and related syndromes.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 5, 2023
    Inventors: Harry C. Dietz, Caitlin J. Bowen
  • Targeted epigenetic therapy against distal regulatory element of TGF?2 expression
    Patent number: 11771703
    Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGF?2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGF?2-associated diseases, disorders and/or conditions.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 3, 2023
    Assignee: The Johns Hopkins University
    Inventors: Harry C. Dietz, Joseph Shin
  • Map kinase pathway targets for the treatment of Marfan syndrome
    Patent number: 11692028
    Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: July 4, 2023
    Assignee: The Johns Hopkins University
    Inventors: Harry C. Dietz, Jefferson J. Doyle, Alexander J. Doyle
  • TARGETING CAPN9/CAPNS2 ACTIVITY AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF MYOFIBROBLAST DIFFERENTIATION AND ASSOCIATED PATHOLOGIES
    Publication number: 20220296688
    Abstract: Provided herein are, inter alia, compositions and methods for identifying and using agents capable of inhibiting myofibroblast transition as well as methods for treating diseases associated with the same in a subject in need thereof.
    Type: Application
    Filed: December 3, 2021
    Publication date: September 22, 2022
    Inventors: David Kim, Harry C. Dietz
  • TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION
    Publication number: 20220265609
    Abstract: Transforming growth factor ? (TGF?) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGF? genes.
    Type: Application
    Filed: February 4, 2022
    Publication date: August 25, 2022
    Inventors: Harry C. Dietz, Benjamin Edward Kang
  • Targeted epigenetic therapy for inherited aortic aneurysm condition
    Patent number: 11273148
    Abstract: Transforming growth factor ? (TGF?) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGF? genes.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: March 15, 2022
    Assignee: The Johns Hopkins University
    Inventors: Harry C. Dietz, Benjamin Edward Kang
  • Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
    Patent number: 11219670
    Abstract: Provided herein are, inter alia, compositions and methods for identifying and using agents capable of inhibiting myofibroblast transition as well as methods for treating diseases associated with the same in a subject in need thereof.
    Type: Grant
    Filed: September 5, 2015
    Date of Patent: January 11, 2022
    Assignee: The Johns Hopkins University
    Inventors: David Kim, Harry C. Dietz
  • COMPOSITIONS AND METHODS FOR TREATING VASCULAR EHLERS DANLOS SYNDROME AND ASSOCIATED DISORDERS
    Publication number: 20210386740
    Abstract: The present invention relates to compositions and methods for treating vascular Ehlers Danlos Syndrome and associated connective tissue disorders.
    Type: Application
    Filed: October 16, 2019
    Publication date: December 16, 2021
    Inventors: Harry C. Dietz, Caitlin J. Bowen, Juan Francisco Calderon Giadrosic
  • TARGETED EPIGENETIC THERAPY AGAINST DISTAL REGULATORY ELEMENT OF TGFB2 EXPRESSION
    Publication number: 20210275541
    Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGF?2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGF?2-associated diseases, disorders and/or conditions.
    Type: Application
    Filed: March 16, 2018
    Publication date: September 9, 2021
    Inventors: Harry C. Dietz, Joseph Shin
  • TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION
    Publication number: 20200253932
    Abstract: Transforming growth factor ? (TGF?) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGF? genes.
    Type: Application
    Filed: August 31, 2018
    Publication date: August 13, 2020
    Inventors: Harry C. Dietz, Benjamin Edward Kang
  • MAP KINASE PATHWAY TARGETS FOR THE TREATMENT OF MARFAN SYNDROME
    Publication number: 20200247881
    Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.
    Type: Application
    Filed: March 2, 2018
    Publication date: August 6, 2020
    Inventors: Harry C. Dietz, Jefferson J. Doyle, Alexander J. Doyle
  • TARGETING CAPN9/CAPNS2 ACTIVITY AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF MYOFIBROBLAST DIFFERENTIATION AND ASSOCIATED PATHOLOGIES
    Publication number: 20180318405
    Abstract: Provided herein are, inter alia, compositions and methods for identifying and using agents capable of inhibiting myofibroblast transition as well as methods for treating diseases associated with the same in a subject in need thereof.
    Type: Application
    Filed: September 5, 2015
    Publication date: November 8, 2018
    Inventors: David Kim, Harry C. Dietz
  • INTEGRIN-MODULATING THERAPIES FOR TREATING FIBROTIC DISEASE
    Publication number: 20160222122
    Abstract: A method of treating scleroderma and other fibrotic conditions is disclosed. The method includes the step of administering to a subject having a fibrotic condition an effective amount of an agent capable of modulating the activity of one or more integrins. The integrin activity-modulating agent alters cell-matrix interactions, thus reducing the symptoms of the fibrotic condition.
    Type: Application
    Filed: September 15, 2014
    Publication date: August 4, 2016
    Applicant: The Johns Hopkins University
    Inventors: Harry C. Dietz, Elizabeth E. Gerber
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF MARFAN SYNDROME AND ASSOCIATED DISORDERS
    Publication number: 20140148498
    Abstract: The instant invention provides methods and compositions for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The invention further provides pharmaceutical compositions and kits for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.
    Type: Application
    Filed: April 13, 2012
    Publication date: May 29, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Harry C. Dietz, Jefferson J. Doyle, Jennifer Pardo Habashi, Tammy Holm
  • Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
    Patent number: 8597646
    Abstract: The instant invention provides methods and compositions for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The invention further provides pharmaceutical compositions and kits for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: December 3, 2013
    Assignee: The Johns Hopkins University
    Inventors: Harry C. Dietz, Daniel P. Judge, Enid R. Neptune, Ronald Cohn, Jennifer Habashi
  • Methods and Compositons for the Treatment of Marfan Syndrome and Associated Disorders
    Publication number: 20100034806
    Abstract: The instant invention provides methods and compositions for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The invention further provides pharmaceutical compositions and kits for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.
    Type: Application
    Filed: October 25, 2006
    Publication date: February 11, 2010
    Applicant: The Johns Hopkins Umiversity
    Inventors: Harry C. Dietz, Daniel P. Judge, Enid R. Neptune, Ronald Cohn, Jennifer Habashi
  • Delivery construct for antisense nucleic acids and methods of use
    Patent number: 6924096
    Abstract: A novel nucleic acid construct for delivery of antisense targeting sequences is provided. The construct includes intact stem loop structures and an antisense nucleic acid. Optionally, a ribozyme nucleic acid is included in the construct. The construct is useful for inhibition of selected genes in a cell. This allele-specific targeting is also useful in combination with replacement gene therapy.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: August 2, 2005
    Assignee: The Johns Hopkins University School of Medicine
    Inventor: Harry C. Dietz
  • Methods and compositions for identifying disease genes using nonsense-mediated decay inhibition
    Publication number: 20040161765
    Abstract: The invention provides compositions and methods for diagnostic and therapeutic applications of gene identification by nonsense-mediated decay inhibition (GINI). The approach allows the rapid identification of the genes and genetic lesions responsible for monogenic as well as polygenic human genetic disorders. In addition, the approach supports diagnostic typing and therapeutic selection for human cancers and other disorders arising as a result of gene mutations.
    Type: Application
    Filed: April 14, 2004
    Publication date: August 19, 2004
    Inventors: Harry C. Dietz, Eric Noensie